The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel

Gottfried Maya

Status: Unknown

Conditions: Metastatic Prostate Cancer; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer; Metastatic Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01814150

A1AGP1234

Details and patient eligibility

About

Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.

One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein.

Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients.

The investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.

Full description

Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.

One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein

Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in non small cell lung cancer patients.

The investigators aim to prospectively study the association between the baseline plasma level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of docetaxel) and the outcome (response rete, progression free survival, overall survival) of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, stomach cancer, prostate cancer, and bladder cancer.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• patients with metastatic cancer from lung, breast, gastric, prostate, and bladder origin
• patients must be treated with docetaxel based chemotherapy
• patients must sign an informed consent form

Exclusion Criteria

• patients with metastatic cancer other than lung, breast, gastric, prostate, and bladder origin
• patients treated with chemotherapy other than docetaxel
• patients that did not sign an informed consent form

Trial design

200 participants in 1 patient group

Oncology Institute, Meir Medical Center

Description:

Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center